【摘要】 心血管疾病的流行是一个全球性的现象,在我国,其患病率也不断增长。目前尚无有效的治疗方法以解决心肌细胞损失这一关键问题,而干细胞移植很可能成为新的治疗方法。C-kit+心脏干细胞(cardiac stem/progenitor cell,CSCs)的发现证实了CSCs的存在,并为心脏的再生和修复治疗带来了新的曙光。C-kit+CSCs在心肌梗死、心力衰竭等心脏疾病中的作用得到了多项体内外实验及临床试验的证实,但由于目前尚缺乏直接的充分的证据证明内源性或外源性的c-kit+CSCs可分化为相当数量的成熟的具有功能的心肌细胞,其治疗机制尚存争议,同时,将其应用于临床仍面临多个问题。更多还原

【Abstract】 The epidemic of cardiovascular disease( CVD) is a global phenomenon,and the morbidity is increasing rapidly in China. The loss of cardiomyocytes has not been solved yet,which is the critical issue of CVD. And stem cell transplantation may be a new potential therapy. The therapeutic potential of ckit~+ CSCs in cardiac diseases has been proved by plentiful preclinical and clinical studies. But,for the absence of direct and sufficient evidence that either endogenous or exogenous adult c-kit~+ CSCs differentiate into a relevant number of mature functional myocytes,the therapeutic mechanism is still controversial.Meanwhile,the clinical application of c-kit~+ CSCs is still facing a number of issues,such as the optimal delivery and source of cells,the proper number of cells and the regulation of cell defferentiation.更多还原